Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH
Stephen A. Harrison, Mustafa R. Bashir, Sam E. Moussa, et al.
Hepatology Communications (2021) Vol. 5, Iss. 4, pp. 573-588
Open Access | Times Cited: 145

Showing 1-25 of 145 citing articles:

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Stephen A. Harrison, Pierre Bédossa, Cynthia D. Guy, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 6, pp. 497-509
Open Access | Times Cited: 663
NAFLD: Mechanisms, Treatments, and Biomarkers
Fatiha Nassir
Biomolecules (2022) Vol. 12, Iss. 6, pp. 824-824
Open Access | Times Cited: 252
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 203
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial
Stephen A. Harrison, Rebecca Taub, Guy Neff, et al.
Nature Medicine (2023) Vol. 29, Iss. 11, pp. 2919-2928
Open Access | Times Cited: 201
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong Li, Junyan Zou, Wei Ran, et al.
Frontiers in Endocrinology (2023) Vol. 13
Open Access | Times Cited: 152
Novel therapeutic targets for cholestatic and fatty liver disease
Michael Trauner, Claudia Fuchs
Gut (2021) Vol. 71, Iss. 1, pp. 194-209
Open Access | Times Cited: 133
Breakthroughs in therapies for NASH and remaining challenges
Vlad Ratziu, Sven Francque, Arun J. Sanyal
Journal of Hepatology (2022) Vol. 76, Iss. 6, pp. 1263-1278
Open Access | Times Cited: 105
An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease
Eun Young Lee, Hannelie Korf, António Vidal-Puig
Journal of Hepatology (2023) Vol. 78, Iss. 5, pp. 1048-1062
Open Access | Times Cited: 102
Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges
Michail Kokkorakis, Chrysoula Boutari, Michael A. Hill, et al.
Metabolism (2024) Vol. 154, pp. 155835-155835
Open Access | Times Cited: 79
Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
Christoph Grander, Felix Grabherr, Herbert Tilg
Cardiovascular Research (2023) Vol. 119, Iss. 9, pp. 1787-1798
Open Access | Times Cited: 78
Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease
Tingying Jiao, Yuandi Ma, Xiaozhen Guo, et al.
Acta Pharmacologica Sinica (2022) Vol. 43, Iss. 5, pp. 1103-1119
Open Access | Times Cited: 77
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Julian M. Yabut, Daniel J. Drucker
Endocrine Reviews (2022) Vol. 44, Iss. 1, pp. 14-32
Open Access | Times Cited: 75
Reactive Oxygen Species and Oxidative Stress in the Pathogenesis of MAFLD
Kathleen Clare, John Dillon, Paul Brennan
Journal of Clinical and Translational Hepatology (2022) Vol. 10, Iss. 5, pp. 939-946
Open Access | Times Cited: 74
Resmetirom: An Orally Administered, Small-molecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
Gres Karim, Meena B. Bansal
touchREVIEWS in Endocrinology (2023) Vol. 19, Iss. 1, pp. 60-60
Open Access | Times Cited: 68
The first MASH drug therapy on the horizon: Current perspectives of resmetirom
Salvatore Petta, Giovanni Targher, Stefano Romeo, et al.
Liver International (2024) Vol. 44, Iss. 7, pp. 1526-1536
Open Access | Times Cited: 63
NAFLD and NASH: etiology, targets and emerging therapies
Shulin Wei, Li Wang, Paul C. Evans, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 3, pp. 103910-103910
Closed Access | Times Cited: 57
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
Paul Brennan, Ahmed M. Elsharkawy, Timothy J. Kendall, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 10, pp. 679-688
Open Access | Times Cited: 50
Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis
Stephen A. Harrison, Vlad Ratziu, Quentin M. Anstee, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 59, Iss. 1, pp. 51-63
Open Access | Times Cited: 48
New and emerging treatments for metabolic dysfunction-associated steatohepatitis
Monica A. Tincopa, Quentin M. Anstee, Rohit Loomba
Cell Metabolism (2024) Vol. 36, Iss. 5, pp. 912-926
Closed Access | Times Cited: 35
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Maximilian Huttasch, Michael Roden, S. Kahl
Metabolism (2024) Vol. 157, pp. 155937-155937
Open Access | Times Cited: 35
Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond
Allison Soto, Colby Spongberg, Alessandro Martinino, et al.
Biomedicines (2024) Vol. 12, Iss. 2, pp. 397-397
Open Access | Times Cited: 22
Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs
Xing Wan, Jingyuan Ma, He Bai, et al.
Biomolecules (2025) Vol. 15, Iss. 1, pp. 140-140
Open Access | Times Cited: 2
Glucagon like peptide-1 receptor agonists as a promising therapeutic option of metabolic dysfunction associated steatotic liver disease and obesity: hitting two targets with one shot
Eda Kaya, Wing‐Kin Syn, Paul Manka
Current Opinion in Gastroenterology (2025)
Closed Access | Times Cited: 2
Inflammatory and fibrotic mechanisms in NAFLD—Implications for new treatment strategies
Youngmin A. Lee, Scott L. Friedman
Journal of Internal Medicine (2021) Vol. 291, Iss. 1, pp. 11-31
Open Access | Times Cited: 72
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH
Vlad Ratziu, Stephen A. Harrison, V. Loustaud‐Ratti, et al.
Journal of Hepatology (2022) Vol. 78, Iss. 3, pp. 479-492
Open Access | Times Cited: 58
Page 1 - Next Page

Scroll to top